Encouraged by positive customer feedback from early installations, the firm is shifting its sales focus to the ePlex system and respiratory pathogen panel.
The test detects 11 viruses and three bacterial pathogens in approximately one hour and requires two minutes of hands-on time.
The company also cut its net loss in the first half of the year to €6.7 million from €12.4 million in the year-ago period.
The ePlex system integrates sample preparation with GenMark's eSensor technology to enable the detection of multiple molecular targets on a single test cartridge.
The high-throughput system is now approved with the firm's Blood Culture ID, Gastrointestinal, Meningitis/Encephalitis, and the previously approved Respiratory Panel.
The firm has also submitted three other assays for special 510(k) clearance on the Torch system.
By focusing on the clinical scenario, a Duke team developed a gene expression-based model to determine whether a patient's disease is bacterial or viral.
The FilmArray Torch has up to 12 modules per system and can process up to 262 patient samples per day using the firm's syndromic panel tests.
With this clearance, the respiratory pathogen panel is ready to enter the market to aid in accurate patient diagnosis for respiratory illness.
Researchers in Belgium and the UK showed that their custom viral panel on Thermo Fisher's TaqMan qPCR array card is effective in samples from immunocompromised patients.
Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.
Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.
The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.
In Science this week: genetically modified flu virus could be key to new live vaccines, and more.